CureVac N.V.
NASDAQ:CVAC
| Market Cap (Intraday) | 546.27M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $2.69 |
| 50-Day MA | $3.17 |
| 200-Day MA | $5.67 |
CureVac N.V. Stock, NASDAQ:CVAC
Friedrich-Miescher-Strasse 15, TÃ?Â?bingen, Baden Wuerttemberg 72076
Germany
Phone: +49.7071.9883.0
Number of Employees:
Description
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and protein therapy. The company was founded by Ingmar Hoerr and Florian von der MÃ?Â?lbe in 2000 and is headquartered in TÃ?Â?bingen, Germany.